Subscribe
Contact Us
About Us
Advertise
Home
News
News from MM&M
Off the Wire
Newsletters
PMD Profiles
Agency Creative Showcase
Publication Connection
PMD Marketplace
Careers
About Us
Additional Resources
MM&M
MM&M Jobs
MAHF
Voi Consulting
Advertise
Subscribe
Get Listed
Additional Resources
RSS
|
Login
|
Register
Research & Development
Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
June 16, 2009
Loramyc is currently marketed in several EU territories
Nuvo Research and Covidien sign U.S. license and development agreement for Pennsaid(R) and Pennsaid Plus(R)
June 16, 2009
Nuvo will receive an up-front $10 million
OSI Pharmaceuticals Announces Acceptance of Tarceva Supplemental New Drug Application for Review by the U.S. FDA
June 15, 2009
FDA review date expected in January 2010
Eli Lilly and Company Announces New Drug Discovery Initiative
June 15, 2009
Goal is to foster open collaboration between Lilly and global laboratory researchers
New Study Shows Javelin Pharmaceutical's DylojectTM Well-Tolerated in High-Risk Patients with Impaired Renal and Hepatic Function
June 15, 2009
The Company plans to file a New Drug application during the fall of 2009
FDA Accepts Final Section of NDA Filing for LUCASSIN(R)
June 12, 2009
Priority Review Granted
DxNA Submits its Rapid Detection Platform Test for H1N1 to FDA
June 09, 2009
Company's Portable 4.5kg "Lab in a Box" Allows for Rapid Onsite Pathogen Detection
Dyax Announces FDA Accepts for Review the Complete Response Submission for DX-88 in Hereditary Angioedema
June 08, 2009
FDA action date of December 1, 2009
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring
June 04, 2009
Company to Focus Operations on Continuing the Advancement of ANA598
Positive Outcome Reached at 16 Weeks for Avexa's ATC Phase III Trial
June 04, 2009
DSMB recommends continuation of the ATC Phase III Trial after review of the data
PPD Announces Takeda to Conduct Additional Study for Alogliptin MAA in the EU
June 03, 2009
Takeda to postpone MAA submissions for alogliptin and alogliptin/ACTOS
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
June 02, 2009
Potential Seven Years Market Exclusivity in PHN Pending Product Approval
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
May 11, 2009
Oforta is currently approved in the U.S. for use as a second-line therapy to treat adults with B-cell CLL
ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America
May 04, 2009
Pimavanserin is a new chemical entity (NCE) currently in Phase III development
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
April 30, 2009
Two Phase 3 studies to start in the second half of this year
Simulations Plus Releases DDDPlus Version 3.0
April 29, 2009
Major Update to One-of-a-Kind Software Increases Value to Formulation Scientists
Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense in Advanced Melanoma
April 29, 2009
Final DMB Safety Review and Futility Analysis Next Month
Skinvisible's DermSafe(R) Hand Sanitizer Kills Swine Flu Virus
April 28, 2009
Prevention Available to Combat Spread of Viruses
Isotechnika announces Phase 3 ESSENCE data meets primary endpoint in psoriasis
April 28, 2009
ESSENCE study results confirm the safety profile of voclosporin
Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
April 27, 2009
Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
April 22, 2009
Genentech and Roche Remain Committed to Avastin Adjuvant Colon, Breast and Lung Cancer Programs
Alkermes Completes Enrollment for Registration Study of VIVITROL in Patients with Opioid Dependence
April 21, 2009
Clinical Development Program Expanded with Phase 3b Study in Healthcare Professionals
Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and CEO
April 08, 2009
Alan L. Crane named Chairman of the Board
Latest News
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Most Popular
Most Emailed
Most Recent
Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
FDA Approves Exalgo Extended-Release Tablets
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Lilly to Acquire European Rights to Pfizer Animal Health Assets
Alun Malone Joins Millennium Laboratories As New Business Development Executive
CSL Behring Receives FDA Approval of Hizentra™
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Popular Topics
Acquisition
Agency
Animal Health
Biopharmaceutical
Biotech
Business
Clinical Management
Collaboration
Marketing & Communications
Medical Device
Medical Equipment
Merger
New Company
New Hire
New Hires
Personnel
Pharmaceutical
Pharmaceutical Marketplace
Pharmaceutical Products
Pipeline
Product Acquisition
Product Launch
Product Promotion
Regulatory
Research & Development